Al Sharef O, Feely J, Kavanagh P V, Scott K R, Sharma S C
Department of Pharmacology and Therapeutics, Trinity Centre for Health Sciences, St James's Hospital, Dublin 8, Ireland.
Biomed Chromatogr. 2007 Nov;21(11):1201-6. doi: 10.1002/bmc.877.
The measurement of the urinary free cortisol-cortisone ratio has been reported to be a sensitive indicator of renal 11 beta-hydroxysteroid dehydrogenase type 2 (11 beta-HSD 2) activity. This converts biologically active cortisol to inactive cortisone. A decrease in its activity (e.g. through disease or inhibition caused by a therapeutic agent or a foodstuff) may increase cortisol levels and susceptibility towards hypertension. The method presented here uses a simple isocratic tandem column HPLC system. The method has been validated and found to be robust and reproducible. The lower limit of quantification (LLOQ) was found to be 10 ng/mL for both cortisol and cortisone. Samples of urine (n = 99) from patients, most of whom were on complex combinations of drugs, were analyzed and 92% of samples were found to give successful results with this method (cortisol and cortisone above LLOQ). The ratio ranged from 0.07 to 5.61. No interferences were noted from the drugs that the patients were taking. It was also found that a morning spot urine sample gave comparable results to 24 h collection samples, thus making sample collection much easier.
尿游离皮质醇与可的松比值的测定据报道是肾2型11β-羟基类固醇脱氢酶（11β-HSD 2）活性的敏感指标。该酶可将具有生物活性的皮质醇转化为无活性的可的松。其活性降低（如因疾病或治疗药物或食品引起的抑制）可能会增加皮质醇水平以及患高血压的易感性。本文介绍的方法采用简单的等度串联柱高效液相色谱系统。该方法已经过验证，结果可靠且可重复。皮质醇和可的松的定量下限（LLOQ）均为10 ng/mL。对来自患者的99份尿液样本（其中大多数患者正在使用复杂的药物组合）进行了分析，结果发现92%的样本采用该方法得到了成功结果（皮质醇和可的松高于LLOQ）。该比值范围为0.07至5.61。未发现患者所服用药物产生干扰。还发现晨尿样本与24小时收集样本的结果相当，从而使样本采集更加简便。
